stockrow
Saturday 7 November 2026
Export RGNX’s income statement to Excel — free account
REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.
- Revenue
- −69.2%
- EPS
- +48.0%
- Free cash flow
- +168.1%
Quarter to September 2026, against a year earlier
7.56
0.18
+2.44%
Follow RGNX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.19 | 3.63 | 5.00 | 4.36 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.90) | (10.17) | (5.77) | (14.20) | |
P/B ratio |
3.32 | 8.82 | 20.84 | 7.23 | |
Price to Tangible BV |
3.32 | 8.82 | 20.84 | 7.23 | |
EV/Sales |
1.60 | 3.05 | 3.36 | 3.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.62) | (2.16) | (1.26) | (4.18) | |
EV/FCF |
(1.59) | (2.13) | (1.25) | (4.10) | |
Quick Ratio |
3.84 | 2.57 | 2.26 | 2.17 | |
Current Ratio |
4.74 | 2.86 | 2.62 | 2.38 | |
Net Debt/EBITDA |
0.00 | (3.25) | 1.87 | 4.28 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.31 | 0.36 | 0.21 | 0.37 | |
Operating CF/Net income |
0.00 | (2.74) | 0.85 | 0.78 | |
Capex/Depreciation |
0.00 | (0.23) | (0.41) | (0.13) | |
Interest Coverage |
(4.76) | 3.76 | (9.57) | (4.69) | |
Research and Development Expense of Revenue |
665.89% | 51.92% | 896.90% | 196.50% | |
Selling, General and Administrative Expense of Revenue |
224.61% | 20.01% | 333.27% | 73.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 8.38% | 134.79% | 27.61% | |
Graham Net Nets |
0.01 | (0.12) | (0.31) | (0.09) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(42.69%) | (31.64%) | (66.83%) | (26.11%) | |
Free Cash Flow Yield |
(31.50%) | (39.46%) | (53.81%) | (17.02%) | |
Revenue per Share |
0.14 | 2.05 | 0.12 | 0.59 | |
Operating CF per Share |
0.00 | (1.18) | (1.45) | (1.01) | |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
0.00 | (1.19) | (1.48) | (1.02) | |
Cash per Share |
3.85 | 2.00 | 2.87 | 4.46 | |
Shareholders Equity per Share |
2.27 | 1.36 | 0.40 | 1.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.27 | 1.36 | 0.40 | 1.99 | |
Free Cash Flow |
38.42 | (63.00) | (77.42) | (52.80) | |
Working Capital |
253.21 | 153.54 | 115.41 | 163.19 | |
Capital Expenditures |
(0.19) | (0.76) | (1.23) | (0.51) | |
Net Current Asset Value |
2.89 | (78.70) | (134.30) | (69.02) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.19 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.94 | 63.48 | 14.12 | 23.43 | |
Average Payables |
17.87 | 18.60 | 20.13 | 22.08 | |
Average Assets |
495.62 | 483.82 | 416.41 | 459.51 | |
Average Common Equity |
154.75 | 142.72 | 147.64 | 181.19 |
Columns are period end dates · fundamentals updated 6 Nov 2026